Current Status of Revisions to the Lugano Classification in Lymphoma.

In the decade since publication of the Lugano Classification (Cheson et al, J Clin Oncol 2014,32:3059-3068; Barrington et al, J Clin Oncol 2014, 32:3048-3058), major advances in lymphoma therapy and assessment, including metabolic tumor volume (MTV) and circulating tumor DNA (ctDNA) prompted a workshop at the International Conference on Malignant Lymphoma-17 entitled "Lugano Classification: Looking Toward the Future", to determine whether a revision was warranted and what it should look like. This report summarizes the conclusions of that workshop and a subsequent questionnaire of the participants. It was concluded that, whereas, minor modifications could be made now, the current classification should remain the standard until the clinical benefit of MTV and ctDNA are firmly established and practical considerations demonstrated. An ICML sponsored standing committee will monitor progress and ensure that a revision of the Lugano Classification will be proposed when warranted.